Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ABOS Acumen Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ABOS
Price (delayed)
$1.07
Market cap
$64.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.94
Enterprise value
$63.95M
Highlights
The company's debt fell by 3.4% YoY
The company's quick ratio has shrunk by 74% YoY but it rose by 24% QoQ
Acumen Pharmaceuticals's net income has plunged by 108% YoY and by 14% from the previous quarter
Acumen Pharmaceuticals's EPS has plunged by 83% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of ABOS
Market
Valuations
Earnings
Shares outstanding
60.57M
Market cap
$64.81M
Enterprise value
$63.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$126.61M
Net income
-$116.25M
EBIT
-$112.16M
EBITDA
-$111.98M
Free cash flow
-$102.56M
Per share
Balance sheet
Liquidity
EPS
-$1.94
EPS diluted
-$1.94
Free cash flow per share
-$1.69
Book value per share
$2.57
Revenue per share
$0
TBVPS
$3.38
Total assets
$204.48M
Total liabilities
$48.96M
Debt
$29.53M
Equity
$155.52M
Working capital
$135.63M
Debt to equity
0.19
Current ratio
8.02
Quick ratio
7.73
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-46.5%
Return on equity
-58.2%
Return on invested capital
-51.7%
Return on capital employed
-60.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABOS stock price
How has the Acumen Pharmaceuticals stock price performed over time
Intraday
2.88%
1 week
4.9%
1 month
-0.93%
1 year
-60.81%
YTD
-37.79%
QTD
-2.73%
Financial performance
How have Acumen Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$126.61M
Net income
-$116.25M
Gross margin
N/A
Net margin
N/A
Acumen Pharmaceuticals's net income has plunged by 108% YoY and by 14% from the previous quarter
Acumen Pharmaceuticals's operating income has shrunk by 92% YoY and by 11% QoQ
Price vs fundamentals
How does ABOS's price correlate with its fundamentals
Growth
What is Acumen Pharmaceuticals's growth rate over time
Valuation
What is Acumen Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Acumen Pharmaceuticals's EPS has plunged by 83% YoY and by 13% from the previous quarter
The company's equity fell by 41% YoY and by 14% QoQ
The P/B is 30% less than the last 4 quarters average of 0.6
Efficiency
How efficient is Acumen Pharmaceuticals business performance
ABOS's return on equity has dropped by 154% year-on-year and by 29% since the previous quarter
ABOS's ROA has dropped by 124% year-on-year and by 24% since the previous quarter
ABOS's ROIC has plunged by 94% YoY and by 26% from the previous quarter
Dividends
What is ABOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABOS.
Financial health
How did Acumen Pharmaceuticals financials performed over time
The company's quick ratio has shrunk by 74% YoY but it rose by 24% QoQ
ABOS's current ratio has dropped by 73% year-on-year but it is up by 24% since the previous quarter
The company's debt is 81% lower than its equity
The debt to equity has soared by 58% YoY and by 19% from the previous quarter
The company's equity fell by 41% YoY and by 14% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.